Breaking News

Sobi to Cease ReFacto Manufacturing in the First Quarter of 2024

Sobi has been responsible for commercial production of ReFacto and its predecessor since 1998.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The Stockholm, Sweden-based biopharmaceutical company Sobi said that its contract with Pfizer for the manufacture of drug substance for ReFacto AF/Xyntha (ReFacto) has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous expiry date at the end of 2025. Manufacturing of drug substance for ReFacto will be transferred to Pfizer’s production unit in Ireland, ensuring continued patient access. Sobi will start the process of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters